Literature DB >> 23922242

Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes.

Yun Liu1, Chelsea D Higgins, Cathie M Overstreet, Kanti R Rai, Nicholas Chiorazzi, Jonathan R Lai.   

Abstract

Chronic lymphocytic leukemia (CLL) is a clonal disease of a subset of human B lymphocytes. Although the cause of the disease is unknown, its development and evolution appear to be promoted by signals delivered when B-cell receptors (BCRs) engage (auto)antigens. Here, using a peptide phage display library of enhanced size and diverse composition, we examined the binding specificity of a recombinant monoclonal antibody (mAb) constructed with the heavy chain and light chain variable domains of a CLL BCR that does not exhibit somatic mutations. As determined by testing the peptides identified in the selected peptide phage pool, this CLL-associated unmutated mAb bound a diverse set of sequences, some of which clustered in families based on amino acid sequence. Synthesis of these peptides and characterization of binding with the CLL-associated mAb revealed that mAb-peptide interactions were generally specific. Moreover, the mAb-peptide interactions were of lower affinities (micromolar KD), as measured by surface plasmon resonance, than those observed with a CLL mAb containing somatic mutations (nanomolar KD) and with immunoglobulin heavy chain variable (IGHV)-mutated antibodies selected by environmental antigens. This information may be of value in identifying and targeting B lymphocytes expressing specific BCRs in CLL patients and healthy subjects with monoclonal B lymphocytosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23922242      PMCID: PMC3769532          DOI: 10.2119/molmed.2013.00082

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  32 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  B-cell clones as early markers for chronic lymphocytic leukemia.

Authors:  Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

3.  Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity.

Authors:  T Keitel; A Kramer; H Wessner; C Scholz; J Schneider-Mergener; W Höhne
Journal:  Cell       Date:  1997-12-12       Impact factor: 41.582

4.  Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.

Authors:  Maxime Hervé; Kai Xu; Yen-Shing Ng; Hedda Wardemann; Emilia Albesiano; Bradley T Messmer; Nicholas Chiorazzi; Eric Meffre
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

5.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

Authors:  Kostas Stamatopoulos; Chrysoula Belessi; Carol Moreno; Myriam Boudjograh; Giuseppe Guida; Tatjana Smilevska; Lynda Belhoul; Stefania Stella; Niki Stavroyianni; Marta Crespo; Anastasia Hadzidimitriou; Laurent Sutton; Francesc Bosch; Nikolaos Laoutaris; Achilles Anagnostopoulos; Emili Montserrat; Athanasios Fassas; Guillaume Dighiero; Federico Caligaris-Cappio; Hélène Merle-Béral; Paolo Ghia; Frédéric Davi
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

6.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype.

Authors:  Marcela Torres; Rena May; Matthew D Scharff; Arturo Casadevall
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

9.  Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.

Authors:  N E van Houten; M B Zwick; A Menendez; J K Scott
Journal:  Vaccine       Date:  2006-01-11       Impact factor: 3.641

10.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Authors:  F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

View more
  3 in total

1.  Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates.

Authors:  Mohosin Sarkar; Yun Liu; Junpeng Qi; Haiyong Peng; Jumpei Morimoto; Christoph Rader; Nicholas Chiorazzi; Thomas Kodadek
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

2.  Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2.

Authors:  Benjamin M Larimer; Jeanne M Quinn; Kevin Kramer; Andrey Komissarov; Susan L Deutscher
Journal:  Int J Pept Res Ther       Date:  2015-05-09       Impact factor: 1.931

3.  Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands.

Authors:  Jumpei Morimoto; Mohosin Sarkar; Sophia Kenrick; Thomas Kodadek
Journal:  Bioconjug Chem       Date:  2014-07-30       Impact factor: 4.774

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.